Dermatomyositis Market is estimated to be valued at US$ 493.15 million in 2022 and is expected to reach US$ 696.57 million by 2030, witnessing a CAGR of 4.4% over the forecast period | AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG

Overview:

Dermatomyositis is a rare condition that causes muscle inflammation. It is an inflammatory disorder that affects skin and the muscles. There is no cure, but treatment helps clear the skin rash and regain muscle function and strength. In some cases, dermatomyositis resolves on its own, while in others, symptoms may last for a lifetime. Methotrexate (Trexall) and azathioprine (Azasan, Imuran) are most commonly used drugs to treat dermatomyositis. Mycophenolate mofetil (Cellcept) is also used to treat dermatomyositis.

Global dermatomyositis market is estimated to be valued at US$ 493.15 million in 2022 and is expected to reach US$ 696.57 million by 2030, witnessing a CAGR of 4.4% over the forecast period (2022-2030).

To Get More Business Strategies Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/5250

Drivers:

Increase in focus on the development of novel treatments, increasing number of clinical trials, increasing research and development (R&D) activities, and product launches by major players are major factors expected to boost the growth of the global dermatomyositis market.

Moreover, government funding for clinical research is expected to augment the growth of the global dermatomyositis market. For instance, according to the data published in July 2022 by the Pharmaphorum, the U.K. government announced that US$ 212 million in funding will be invested in improving data infrastructure to enable better research.

Furthermore, increase in research and development by both government and non- government organizations is expected to propel growth of the global dermatomyositis market. For instance, in 2021, the Myositis Association funded two research grants. A grant of around US$ 200,000 had been provided to Dr. Nagaraju, DVM, PhD of Binghamton University in New York (US). The research will focus on the inflammatory muscle changes seen in dermatomyositis.

Moreover, in May 2020, Myositis Association (TMA) announced that recipients of the TMA’s Innovative Research Grant, Dr. Spyridon Megremis, Dr. Janine Lamb, and Prof. Ian Hampson at the University of Manchester developed a novel approach to identify the targets of antibodies produced by the immune system in myositis patients.

Opportunities:

Increasing prevalence of juvenile dermatomyositis worldwide is expected to provide lucrative growth opportunities for players in the global dermatomyositis market. For instance, according to the data published in March 2021 by Orphanet, the prevalence of juvenile dermatomyositis (JDM) is 1 per 250,000-500,000 children, annually. The condition is more common in women than in men (2-5:1 ratio). Moreover, as per the National Organization for Rare Disorders, in 2021, worldwide, the prevalence of dermatomyositis was estimated at 9.63 cases per million people each year. Symptoms usually begin to appear in children between the ages of 5 and 15. Juvenile dermatomyositis affects around 3 in 1,000,000 children.

Restraints:

Side effects of dermatomyositis drugs are expected to hinder growth of the dermatomyositis market. For instance, drugs, such as Octagam 10% causes headache, thrombosis, anaphylactic reactions, nausea, and may cause hemolytic anemia, transfusion-related acute lung injury, and aseptic meningitis syndrome (in rare cases). Moreover, minor chest pain, muscle cramps, back pain, abdominal pain, fainting and dizziness, mild headache, and pain and swelling at injection site are some of the common side effects of dermatomyositis drugs.

COVID-19 Impact:

Since the outbreak of COVID-19, the disease has spread to more than 100 countries around the world. Safety measures, such as nationwide lockdown and travel restrictions, enforced by many governments to curb the spread of the virus also impacted the financial status of businesses in all sectors. Moreover, the pandemic also disrupted manufacturing and supply chain activities of businesses across sectors. Moreover, pandemic has had a negative impact on the production, development, and supply of pharmaceuticals used to treat a variety of diseases, as the outbreak of COVID-19 resulted in the closure of industrial establishments and disruption in the supply chain of pharmaceutical products.

Competitive Landscape:

Key players operating in the global dermatomyositis market are Néovacs, Pfizer Inc., Horizon Therapeutics plc, Mallinckrodt Plc, Kezar Life Sciences Inc., Ermium Therapeutics, Bristol-Myers Squibb Company, CSL Limited, Octapharma AG, AstraZeneca Plc., and Corbus Pharmaceuticals Holdings, Inc., among others

Reasons to buy this Dermatomyositis Market Report

☑ It attempts an analysis of the competing scenario.

☑ The current and exceptional product revenue market.

☑ An in-depth data on the regional investigation and competitive landscape structure.

☑ It benefits in creating an awareness of the important key product segments.

☑ The marketing strategies, opportunities, and development factors are explained.

☑ Dermatomyositis market size estimation and recent advancements in the industry are explained.

Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/5250

The Study Objectives are:

✔ A comprehensive insight into key players operating in the Dermatomyositis Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Dermatomyositis Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Dermatomyositis Industry Impact

Chapter 2 Global Dermatomyositis Competition by Types, Applications, and Top Regions and Countries
2.1 Global Dermatomyositis (Volume and Value) by Type
2.3 Global Dermatomyositis (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Dermatomyositis Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Dermatomyositis Market Analysis
Chapter 6 East Asia Dermatomyositis Market Analysis
Chapter 7 Europe Dermatomyositis Market Analysis
Chapter 8 South Asia Dermatomyositis Market Analysis
Chapter 9 Southeast Asia Dermatomyositis Market Analysis
Chapter 10 Middle East Dermatomyositis Market Analysis
Chapter 11 Africa Dermatomyositis Market Analysis
Chapter 12 Oceania Dermatomyositis Market Analysis
Chapter 13 South America Dermatomyositis Market Analysis
Chapter 14 Company Profiles and Key Figures in Dermatomyositis Business
Chapter 15 Global Dermatomyositis Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology